Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lonza Collaborates Cristal Therapeutics And McSAF to Expand Bioconjugates Offering
Details : Through the new agreement, McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates and antibody-drug conjugate.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
January 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Adcitmer
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Axplora
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.
Product Name : Adcitmer
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 18, 2021
Lead Product(s) : Adcitmer
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Axplora
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
